June 4, 2026

LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit

May 27, 2026

LeonaBio to Participate in Upcoming Medical and Industry Meetings in June

May 7, 2026

LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026

LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.

April 23, 2026

LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer

April 21, 2026

Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data

March 26, 2026

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update

February 3, 2026

LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer

January 9, 2026

Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”

December 18, 2025

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

November 6, 2025

Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update

September 11, 2025

Athira Pharma Announces Reverse Stock Split

August 14, 2025

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025

August 7, 2025

Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

May 13, 2025

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

May 9, 2025

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

February 27, 2025

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

December 6, 2024

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND

November 7, 2024

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

October 22, 2024

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting

September 17, 2024

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

September 3, 2024

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease

August 1, 2024

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

July 31, 2024

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024

July 9, 2024

Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

More News